Literature DB >> 11895100

Interaction of digoxin with antihypertensive drugs via MDR1.

Kohji Takara1, Mikio Kakumoto, Yusuke Tanigawara, Junko Funakoshi, Toshiyuki Sakaeda, Katsuhiko Okumura.   

Abstract

The multidrug transporter MDR1 (P-glycoprotein)-mediated interaction between digoxin and 29 antihypertensive drugs of various types was examined by using the MDR1 overexpressing LLC-GA5-COL150 cells, which were established by transfecting MDR1 cDNA into porcine kidney epithelial LLC-PK1 cells. These cells construct monolayers with tight junctions, and enable the evaluation of transcellular transport. The MDR1 was highly expressed on the apical membrane (urine side). The basal-to-apical and apical-to-basal transcellular transport of [3H]digoxin in LLC-GA5-COL150 cells was time- and temperature-dependent. The basal-to-apical transport of [3H]digoxin was markedly increased, whereas the apical-to-basal transport was decreased in LLC-GA5-COL150 cells, compared with the host LLC-PK1 cells, suggesting that [3H]digoxin was a substrate for MDR1. Most of the Ca2+ channel blockers used here markedly inhibited basal-to-apical transport and increased apical-to-basal transport. Exceptions were diltiazem, nifedipine and nitrendipine, which hardly showed inhibitory effects on transcellular transport of [3H]digoxin. Alpha-blocker doxazosin and beta-blocker carvedilol also inhibited transcellular transport of [3H]digoxin, but none of the angiotensin converting enzyme inhibitors and AT1 angiotensin II receptor antagonists used here were active. These observations will promote understanding of the digoxin-drug interactions resulting from their actions on MDR1, and which may aid in avoiding these unexpected effects of digoxin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895100     DOI: 10.1016/s0024-3205(01)01494-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

Review 1.  The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions.

Authors:  Lawrence M DuBuske
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort.

Authors:  Ying Zhao; Desheng Zhai; Hui He; Tingting Li; Xijing Chen; Hui Ji
Journal:  Eur J Clin Pharmacol       Date:  2009-02-11       Impact factor: 2.953

3.  Population pharmacokinetics of digoxin in elderly patients.

Authors:  Rong Chen; Su-lan Zou; Ming-li Wang; Yan Jiang; Hui Xue; Chun-yan Qian; Zong-ling Xia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-10-25       Impact factor: 2.441

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?

Authors:  Nezihi Baris; Sule Kalkan; Sema Güneri; Volkan Bozdemir; Hulya Guven
Journal:  Eur J Clin Pharmacol       Date:  2006-06-10       Impact factor: 2.953

Review 6.  Drug Interactions with Antihypertensives.

Authors:  Michelle A Fravel; Michael Ernst
Journal:  Curr Hypertens Rep       Date:  2021-03-05       Impact factor: 5.369

Review 7.  ABC of oral bioavailability: transporters as gatekeepers in the gut.

Authors:  C G Dietrich; A Geier; R P J Oude Elferink
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

8.  Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.

Authors:  Tsuyoshi Mikkaichi; Takehiro Suzuki; Tohru Onogawa; Masayuki Tanemoto; Hiroya Mizutamari; Masahiro Okada; Tatsuji Chaki; Satohiro Masuda; Taro Tokui; Nobuaki Eto; Michiaki Abe; Fumitoshi Satoh; Michiaki Unno; Takanori Hishinuma; Ken-Ichi Inui; Sadayoshi Ito; Junichi Goto; Takaaki Abe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.